# hepatocellular carcinoma (HCC) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 27120
- Completion tokens: 11363
- Reasoning tokens: 0
- Total tokens: 38483
- API requests reported: 2
- Elapsed seconds: 77.377
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: DeepSeek

---
# Multidimensional interpretation of the HCC overall-survival prognostic signature

## Critical data-quality warning (read first)

Before any biological interpretation, the statistical input itself must be assessed. The supplied table contains **100 selected genes with uniformly extreme effect sizes**: 97 of 100 are risk-associated, and the majority carry HR values at the machine-precision cap of **5.1847055e+21** (identical value across dozens of genes), with P = 0 and FDR = 0 across all 100 genes. Only 3 genes are protective-associated (CENPVL3, LOC105372753, RP11-506K19.2), each with HR = 1.9287498e-22. The ledger confirms: direction counts = 3 protective / 97 risk-associated; 303 input rows retained for 100 unique genes; 2 duplicated genes/probes; and two genes (Y_RNA, Metazoa_SRP) flagged with direction-conflict across their multiple rows.

These features—saturated HR values, identical effect sizes across unrelated genes, and a 97:3 risk-to-protective imbalance—are **technically suspicious and likely not biologically meaningful in their raw form**. They are consistent with (a) near-zero or near-saturated expression values in a subset of samples producing unstable Cox estimates, (b) a separation/perfect-prediction problem in the survival model, (c) a very small number of events driving extreme HRs, or (d) an artifact of how low-abundance transcripts (rRNA, snRNA, pseudogenes, lncRNAs, olfactory receptors) were handled in normalization. The P = 0 and FDR = 0 values are therefore not informative as evidence of biological effect size; they reflect computational saturation rather than measured biological magnitude.

**This warning does not invalidate the analysis, but it fundamentally changes how the results should be read.** The correct approach is to treat the extreme HRs as unreliable point estimates, use the direction (risk vs. protective) and gene identity as the only usable signal, and interpret the gene list compositionally rather than by HR magnitude. All conclusions below are therefore **exploratory hypotheses**, not established findings.

---

## 1. Overall biological interpretation

The dominant and unambiguous observation is that the risk-associated gene set is **compositionally dominated by non-coding and low-complexity transcripts**: ribosomal RNA pseudogenes (RNA5SP507, RNA5SP359, RPL5P21), small nuclear RNA pseudogenes (RNU6-1134P, RNU6-71P, RNU1-139P, RNU4-72P, RNU4-63P, RNU7-180P, RNU7-159P), 7SK RNA pseudogenes (RN7SKP270, RN7SKP289), Y_RNA and Metazoa_SRP, olfactory receptor genes and pseudogenes (OR5M13P, OR2M7, OR5T2, OR5M5P, OR5M6P, OR5M10, OR11J6P, VN1R96P), intergenic lncRNAs (LINC00454, LINC01672, LINC02787, LINC02645, LINC00701, LINC01665, LINC02265, LINC00603, LINC02135), and numerous uncharacterized locus identifiers (LOC124900247, LOC101928516, LOC105372753, LOC105375303, LOC105371559, LOC105372058) and unmapped Ensembl IDs (ENSG00000283631, ENSG00000283737, ENSG00000285860, ENSG00000286932, ENSG00000287238, ENSG00000287357, ENSG00000287459, ENSG00000288574).

Only a small number of protein-coding genes with known biology appear: **SLC1A6** (glutamate/aspartate transporter), **IRS4** (insulin receptor substrate 4), **CRH** (corticotropin-releasing hormone), **CGB2** (chorionic gonadotropin beta 2), **OTX2** (orthodenticle homeobox 2), **FOXI1** (forkhead box I1), **FOXR2** (forkhead box R2), **TBC1D26** (TBC1 domain family member 26), **MIR182** (microRNA 182), **SPATA31A1** (spermatogenesis-associated 31A1), and **CCDC172** (coiled-coil domain containing 172).

The biological interpretation therefore splits into two layers:

1. **A technical/compositional layer**: the risk signature is largely defined by RNA classes (rRNA, snRNA, Y_RNA, SRP RNA, olfactory receptor pseudogenes) that are typically expressed at very low levels in liver tissue and are prone to mapping artifacts, alignment ambiguity, and unstable low-count statistics. Their apparent association with poor OS in HCC is most plausibly explained by technical artifacts, sample composition differences, or a small number of outlier samples, rather than by a coherent oncogenic program.

2. **A candidate biological layer**: the few well-annotated protein-coding genes (SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, MIR182) are individually linked to processes that can plausibly relate to HCC aggressiveness—glutamatergic signaling and amino-acid transport (SLC1A6), insulin/IGF signaling (IRS4), neuroendocrine/stress signaling (CRH), developmental transcription factors (OTX2, FOXI1, FOXR2), and oncogenic microRNA activity (MIR182). However, these genes do **not** form a single coherent pathway, and their co-occurrence in this list is more consistent with a heterogeneous, sparse signal than with a unified biological program.

The GO/KEGG batch results reinforce this: the only recurrent annotations for the selected genes are narrow and scattered—L-aspartate import/transport and regulation of glucagon secretion (GO terms), Type II diabetes mellitus, regulation of lipolysis in adipocytes, and long-term depression (KEGG). These are driven almost entirely by SLC1A6 and IRS4 and do not represent a liver-cancer-specific program. The STRING network evidence is similarly dominated by the olfactory-receptor cluster (OR2M7, OR5M10, OR5T2 connecting to ARRB1, ARRB2, GNAL, GNB1, GNG13) and by SLC1A6's interactions with SPTBN2, SLC1A1, ARHGEF11, KAT5, and RORA.

**Overall synthesis**: The current prognostic signature is not a coherent biological program. It is best described as a **technical artifact-suspect, compositionally heterogeneous risk signature** with a small number of biologically plausible candidate genes (SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, MIR182) embedded in a large background of non-coding and low-complexity transcripts. The most defensible interpretation is that the extreme HR values reflect a statistical separation artifact, and that the biologically interpretable signal is confined to a handful of genes whose direction (risk-associated) is consistent with known HCC aggressiveness biology but whose magnitude is not trustworthy.

---

## 2. Core biological programs

Given the data-quality issues, I identify **three** core programs rather than five, because the evidence supports only these and forcing additional programs would require speculative grouping of unrelated transcripts.

### Program 1: Amino-acid/glutamate transport and metabolic reprogramming

- **Direction**: risk-associated (SLC1A6, HR = 5.185e+21; IRS4, HR = 5.185e+21)
- **Supporting genes**: SLC1A6, IRS4
- **Pathway**: GO: L-aspartate import across plasma membrane (GO:0140009); L-aspartate transmembrane transport (GO:0070778); Reactome: Glutamate Neurotransmitter Release Cycle; SLC-mediated transport of amino acids
- **Explanation**: SLC1A6 (EAAT4) is a high-affinity glutamate/aspartate transporter whose expression is normally brain-enriched (GTEx: highest in brain regions, ~2.6–7.5 TPM; near-zero in most peripheral tissues including liver). Its appearance as a top risk gene in liver tumor tissue is biologically surprising and raises the possibility of either (a) aberrant expression in a tumor subpopulation, or (b) a mapping artifact from a homologous sequence. IRS4 is an insulin receptor substrate with roles in insulin/IGF signaling, which is well-established in HCC growth and metabolism. The GO/KEGG batch hits (Type II diabetes mellitus, regulation of lipolysis in adipocytes) are driven by these two genes and point toward metabolic signaling, though not specifically liver-cancer metabolism.
- **Evidence strength**: Weak-to-moderate. The direction is consistent with metabolic reprogramming in aggressive HCC, but only two protein-coding genes support it, and SLC1A6's liver expression is normally negligible. The KEGG/GO enrichment is not a formal statistical enrichment test; it is a retrieved annotation list.
- **Major limitation**: The pathway is defined by two genes, one of which (SLC1A6) is not normally expressed in liver. The association may reflect tumor-cell heterogeneity or technical artifact.

### Program 2: Neuroendocrine/stress and developmental transcription-factor signaling

- **Direction**: risk-associated (CRH, HR = 1.51e+06; OTX2, HR = 5.185e+21; FOXI1, HR = 6.63e+13; FOXR2, HR = 5.185e+21)
- **Supporting genes**: CRH, OTX2, FOXI1, FOXR2
- **Pathway**: No single standardized pathway unifies these genes; the closest are developmental/transcription-factor ontologies (GO: DNA-binding transcription factor activity for FOXI1/FOXR2/OTX2) and neuropeptide signaling (CRH).
- **Explanation**: CRH encodes corticotropin-releasing hormone, a neuropeptide not normally expressed in liver; its detection in liver tumor tissue could reflect neuroendocrine differentiation or an artifact. OTX2, FOXI1, and FOXR2 are developmental transcription factors whose aberrant reactivation is a recognized theme in aggressive cancers (OTX2 in medulloblastoma; FOXR2 in several tumor types). Their co-occurrence as risk genes in HCC suggests possible reactivation of developmental transcriptional programs, but the evidence is sparse and the genes are not known to cooperate in a single pathway.
- **Evidence strength**: Weak. The genes share a "developmental/neuroendocrine" theme but no validated pathway membership. No network evidence connects them.
- **Major limitation**: No pathway-level support; the grouping is thematic rather than mechanistic.

### Program 3: Non-coding RNA and pseudogene transcriptional noise (technical/compositional)

- **Direction**: risk-associated (majority of the list)
- **Supporting genes**: RNA5SP507, RNA5SP359, RPL5P21, RNU6-1134P, RNU6-71P, RNU1-139P, RNU4-72P, RNU4-63P, RNU7-180P, RNU7-159P, RN7SKP270, RN7SKP289, Y_RNA, Metazoa_SRP, OR5M13P, OR2M7, OR5T2, OR5M5P, OR5M6P, OR5M10, OR11J6P, VN1R96P, and the many RP11-/AC-/LINC- loci
- **Pathway**: No standardized pathway; these are RNA classes (rRNA/snRNA/7SK/Y/SRP RNA) and olfactory receptor pseudogenes.
- **Explanation**: The overwhelming majority of risk-associated genes are non-coding RNA pseudogenes, small RNAs, olfactory receptor pseudogenes, and uncharacterized loci. These are among the most difficult transcripts to quantify reliably in RNA-seq: they are low-abundance, multi-mapped, and prone to alignment ambiguity. Their uniform extreme HRs (identical value 5.1847055e+21) are the hallmark of a statistical separation problem, not a biological effect. This "program" is therefore best interpreted as a **technical artifact signature** reflecting unstable estimation for low-count features, possibly compounded by sample composition differences (e.g., varying non-parenchymal cell content) or a small number of outlier tumors.
- **Evidence strength**: The statistical pattern (identical saturated HRs) is strong evidence of artifact. The biological interpretation as a "program" is not meaningful.
- **Major limitation**: This is not a biological program; it is a technical warning that must be addressed before any of the other programs are interpreted.

**Programs deliberately not included**: I did not elevate a "G-protein coupled receptor signaling" program despite the OR-gene cluster and STRING connections to ARRB1/ARRB2/GNAL/GNB1/GNG13, because (a) the genes are olfactory receptors/pseudogenes not normally expressed in liver, (b) the pathway recurrence (4 genes) is driven by the same low-quality OR cluster, and (c) the STRING edges are predicted/curated interactions in a non-liver context, not evidence of HCC-relevant signaling. Similarly, I did not create a "microRNA regulatory" program from MIR182 alone, because a single gene does not constitute a program under the stated rules.

---

## 3. Key genes and interaction modules

I identify **six** key candidates, selected for biological plausibility and directional consistency, not for HR magnitude.

### 1. SLC1A6 (risk-associated; HR = 5.185e+21)
- **Statistical direction**: Risk-associated in this dataset.
- **Potential role**: Glutamate/aspartate transporter (EAAT4); in the context of HCC, aberrant expression could support glutamine/glutamate metabolic reprogramming, which is a recognized HCC dependency. The GO batch links it to L-aspartate import and transport.
- **Proposed relationships**: STRING lists predicted interactions with SPTBN2, SLC1A1, ARHGEF11, KAT5, and RORA (confidence 0.90–0.95). These are **predicted/curated protein interactions**, not direct physical evidence in liver tissue. SLC1A1 is a pathway co-member (same SLC family, same transport function). No direct physical interaction in HCC is established.
- **Evidence grounding**: Direct input (risk direction); GTEx (brain-enriched, near-absent in liver—raises a specificity concern); Reactome (glutamate release cycle, SLC-mediated amino-acid transport); QuickGO (transporter activity); STRING (predicted interactions). These are **not independent** in the sense that they all derive from the same gene annotation databases.

### 2. IRS4 (risk-associated; HR = 5.185e+21)
- **Statistical direction**: Risk-associated.
- **Potential role**: Insulin receptor substrate 4; connects insulin/IGF signaling to PI3K/AKT and MAPK pathways, both central to HCC proliferation and survival. The KEGG batch hits (Type II diabetes mellitus, regulation of lipolysis in adipocytes) reflect IRS4's canonical role in metabolic insulin signaling.
- **Proposed relationships**: Pathway co-membership with insulin/IGF signaling components; no direct physical interaction evidence in this dataset.
- **Evidence grounding**: Direct input; KEGG annotation; literature on IRS4 in cancer is sparse but IRS1/IRS2 are well-established in HCC. The evidence for IRS4 specifically in HCC is **insufficient** without independent validation.

### 3. CRH (risk-associated; HR = 1.51e+06)
- **Statistical direction**: Risk-associated.
- **Potential role**: Corticotropin-releasing hormone; not a canonical liver gene. Its detection may reflect neuroendocrine differentiation, stress-axis signaling, or a mapping artifact. CRH has been studied in some cancers for paracrine/autocrine growth effects, but not in HCC.
- **Proposed relationships**: None supported by this dataset.
- **Evidence grounding**: Direct input only. No pathway, tissue, or interaction evidence links CRH to HCC. **Insufficient evidence** for a biological role in HCC.

### 4. OTX2 (risk-associated; HR = 5.185e+21)
- **Statistical direction**: Risk-associated.
- **Potential role**: Developmental homeobox transcription factor; well-characterized oncogene in medulloblastoma and some other embryonal tumors. In HCC, aberrant reactivation of developmental TFs is a plausible but unproven mechanism.
- **Proposed relationships**: None supported by this dataset.
- **Evidence grounding**: Direct input; literature on OTX2 in other cancers (developmental TF reactivation). No HCC-specific evidence in this pack. **Exploratory hypothesis**.

### 5. FOXR2 (risk-associated; HR = 5.185e+21) and FOXI1 (risk-associated; HR = 6.63e+13)
- **Statistical direction**: Both risk-associated.
- **Potential role**: Forkhead-box transcription factors. FOXR2 has been reported as an oncogene in several cancers; FOXI1 is linked to ion transport and developmental programs. Neither is an established HCC driver.
- **Proposed relationships**: Pathway co-membership only in the broad sense of "DNA-binding transcription factor activity" (GO: MF:protein binding, 6 genes). No direct interaction.
- **Evidence grounding**: Direct input; GO annotation (transcription factor activity); literature on FOXR2 in other cancers. **Exploratory hypothesis**.

### 6. MIR182 (risk-associated; HR = 5.185e+21)
- **Statistical direction**: Risk-associated.
- **Potential role**: Oncogenic microRNA in multiple cancers, including reports in ovarian carcinoma (PubMed 22790015) and inflammatory bone resorption (PubMed 31908034). In HCC, miR-182 has been studied as an oncomiR in some reports.
- **Proposed relationships**: Regulatory interaction (microRNA targeting mRNAs) is the expected mode, but no target genes are identified in this dataset.
- **Evidence grounding**: Direct input; literature (oncomiR in other cancers). HCC-specific miR-182 evidence exists in the broader literature but was not retrieved in this pack. **Exploratory hypothesis**.

**Interaction-module note**: The only network module with multiple selected genes is the olfactory-receptor cluster (OR2M7, OR5M10, OR5T2) connecting to ARRB1/ARRB2/GNAL/GNB1/GNG13 via STRING. These are **predicted interactions in a sensory-signaling context** and are almost certainly irrelevant to HCC biology, given that olfactory receptors are not canonically expressed in liver tumors. I do not elevate this module to a key finding.

**Interaction-type clarification**: Across all candidates, the only relationship types supported by the current evidence are (a) **pathway co-membership** (SLC1A6 with SLC1A1 in SLC-mediated amino-acid transport; IRS4 in insulin signaling), (b) **predicted protein interactions** from STRING (SLC1A6–SPTBN2, SLC1A6–KAT5, etc.), and (c) **regulatory interaction** as the expected mode for MIR182. No direct physical interaction in HCC tissue is established for any pair. Co-expression is not demonstrated in this dataset.

---

## 4. Validation priorities

### Priority 1: Technical artifact check (Confounding / composition check)
- **Why**: The saturated HR values (5.185e+21 across dozens of genes), the 97:3 risk-to-protective imbalance, and the dominance of low-abundance non-coding transcripts strongly suggest a statistical separation artifact. No biological interpretation is trustworthy until this is resolved.
- **Current evidence**: Identical extreme HRs; P = 0 and FDR = 0 across all genes; direction-conflict flags on Y_RNA and Metazoa_SRP.
- **External evidence**: No external validation performed (independent-cohort status = not available).
- **Next step**: Re-run survival analysis with (a) filtering of low-expression genes (e.g., requiring >1 CPM in >20% of samples), (b) Firth's penalized Cox regression or exact logistic regression to handle separation, (c) leave-one-out or bootstrap stability checks, and (d) examination of whether the extreme HRs are driven by a small number of samples with zero/near-zero expression.
- **Conclusion status**: This is the **most important priority** and should be treated as **established evidence of a data-quality problem**, not as a biological finding.

### Priority 2: SLC1A6/glutamate-aspartate transport in HCC (Mechanistic hypothesis)
- **Why**: SLC1A6 is the most biologically coherent risk gene with a clear molecular function (glutamate/aspartate transport) and pathway context (amino-acid transport, glutamate metabolism). Its near-absence in normal liver (GTEx) makes its appearance here either a genuine tumor-specific event or an artifact—either way it deserves resolution.
- **Current evidence**: Risk direction; GO/Reactome annotations; STRING predicted interactions.
- **External evidence**: Glutamine/glutamate metabolism is a recognized HCC dependency in the broader literature; SLC1A6 itself has no established HCC role.
- **Next step**: qPCR/immunohistochemistry on an independent HCC cohort to confirm expression; functional assays (knockdown/overexpression) in HCC cell lines to test proliferation/migration effects; metabolomics to assess glutamate/aspartate flux.
- **Conclusion status**: **Exploratory hypothesis**.

### Priority 3: IRS4 and insulin/IGF signaling (Therapeutic target / Mechanistic hypothesis)
- **Why**: Insulin/IGF signaling is a validated HCC-relevant pathway, and IRS4's risk direction is consistent with oncogenic signaling. If confirmed, IRS4 could be a tractable target.
- **Current evidence**: Risk direction; KEGG annotations (Type II diabetes, lipolysis regulation).
- **External evidence**: IRS1/IRS2 are established in HCC; IRS4-specific HCC data are lacking. The drug-target evidence (ChEMBL, 5/100 genes) does not specifically implicate IRS4 as a validated HCC target.
- **Next step**: Confirm IRS4 protein expression in HCC tissue; test IRS4 knockdown in HCC cell lines; assess PI3K/AKT pathway activation.
- **Conclusion status**: **Exploratory hypothesis**. The existence of insulin-pathway drugs does not constitute evidence that IRS4 is an effective HCC target.

### Priority 4: MIR182 as a prognostic biomarker (Biomarker)
- **Why**: MicroRNAs are stable in plasma and tissue and are attractive biomarkers. MIR182 has prior oncomiR literature in other cancers.
- **Current evidence**: Risk direction in this dataset only.
- **External evidence**: PubMed records link miR-182 to ovarian carcinoma (22790015) and inflammatory bone resorption (31908034)—both non-HCC contexts. HCC-specific miR-182 literature exists but was not retrieved here.
- **Next step**: Measure miR-182 in an independent HCC cohort (tissue and/or plasma) with survival follow-up; test correlation with known HCC biomarkers (AFP, etc.).
- **Conclusion status**: **Exploratory hypothesis**.

### Priority 5: Non-coding RNA / pseudogene signature as a composition marker (Confounding or composition check)
- **Why**: The dominance of rRNA/snRNA/Y_RNA/pseudogene transcripts could reflect tumor purity, non-parenchymal cell content, or RNA-quality differences rather than biology. Understanding this is essential before any of the above hypotheses are pursued.
- **Current evidence**: The composition of the risk list itself.
- **External evidence**: Y-RNA has been proposed as a cancer biomarker (PubMed 32423154) and as a cell-type-specific extracellular-vesicle marker (PubMed 32944168), which supports the idea that these transcripts track cell composition.
- **Next step**: Estimate tumor purity (e.g., via ESTIMATE or copy-number-based methods) and cell-type deconvolution (e.g., CIBERSORTx) in the same samples; correlate the non-coding signature with purity estimates.
- **Conclusion status**: **Supported hypothesis** that the signature tracks composition; the biological meaning is **insufficient evidence**.

---

## 5. Evidence grounding summary

| Claim | Direct input | Pathway/ontology | Protein/regulatory | Disease-association | Expression/tissue | Genetic/clinical | Drug/therapeutic | Literature |
|---|---|---|---|---|---|---|---|---|
| SLC1A6 risk direction | Yes (HR extreme) | Yes (GO, Reactome) | Yes (STRING predicted) | No | Yes (GTEx: brain-enriched, liver-low) | No | No | Partial (glutamate transporters in other contexts) |
| IRS4 risk direction | Yes | Yes (KEGG) | No | Partial (IRS1/2 in HCC) | No | No | No | Partial |
| CRH risk direction | Yes | No | No | No | No | No | No | No |
| OTX2/FOXR2/FOXI1 risk | Yes | Yes (TF activity) | No | Partial (other cancers) | No | No | No | Partial (other cancers) |
| MIR182 risk | Yes | No | Regulatory (expected) | Partial (other cancers) | No | No | No | Yes (ovarian, bone) |
| Non-coding/pseudogene artifact | Yes (saturated HRs) | No | No | No | Yes (RNA classes) | No | No | Partial (Y-RNA biomarkers) |

**Independence caveat**: The GO, Reactome, QuickGO, and STRING records for SLC1A6 all derive from the same underlying gene-annotation infrastructure and are **not independent** sources. GTEx expression is independent of the pathway annotations but is not independent of the sequencing technology that produced the input data. The literature records (PubMed/Europe PMC) are independent of the input statistics but are not independent of each other when they cite the same primary studies.

**Conflict note**: The only explicit conflict in the data is the direction-conflict flags on Y_RNA (168 rows) and Metazoa_SRP (37 rows), meaning these features had inconsistent risk/protective directions across their multiple mapped rows. This is itself evidence of mapping instability for multi-mapped RNA classes.

---

## 6. Limitations and alternative explanations

### Limitation 1: Statistical separation / perfect-prediction artifact
The identical saturated HR values (5.1847055e+21) across dozens of unrelated genes are the signature of a Cox-model separation problem, typically caused by a small number of events and/or near-zero expression in a subset of samples. This is the single most important limitation and affects every downstream interpretation. **Investigation**: Firth penalized regression, exact methods, bootstrap stability, and inspection of per-gene expression distributions in the extreme-risk versus other groups.

### Limitation 2: Tissue and cell-composition differences
Liver tumor tissue contains variable proportions of hepatocytes, immune cells, stellate cells, and endothelial cells. The non-coding RNA and olfactory-receptor signatures could track these composition differences rather than tumor biology. **Investigation**: Cell-type deconvolution, tumor-purity estimation, and single-cell or spatial transcriptomics to localize the signal.

### Limitation 3: Low-expression and multi-mapping artifacts
rRNA, snRNA, Y_RNA, SRP RNA, and olfactory receptor pseudogenes are among the most difficult features to quantify reliably. Multi-mapped reads and pseudogene homology create alignment ambiguity, which the direction-conflict flags on Y_RNA and Metazoa_SRP directly demonstrate. **Investigation**: Re-alignment with multi-mapping-aware tools, exclusion of multi-mapped features, and validation by qPCR or NanoString.

### Limitation 4: Disease severity, treatment exposure, and clinical confounding
OS as an endpoint conflates tumor biology with treatment response, liver function, and comorbidities (e.g., cirrhosis, hepatitis status). The extreme HRs could partly reflect a small subgroup of very aggressive or heavily pretreated tumors. **Investigation**: Multivariable Cox models adjusting for stage, grade, AFP, cirrhosis, and treatment; stratified analysis.

### Limitation 5: Association-versus-causation ambiguity and lack of external validation
No independent-cohort statistic was supplied (external validation status = not available). All biological interpretations are therefore associations within a single dataset, and the extreme values prevent even a reliable ranking of effect sizes. Pathway, interaction, tissue, and literature evidence are contextual only and do not constitute replication. **Investigation**: Independent-cohort survival analysis with the same genes; only concordant direction with nominal significance in an external cohort would constitute replication.

---

## Final synthesis and conclusion

The current HCC overall-survival signature is dominated by a **technical artifact-suspect pattern**: 97 of 100 genes are risk-associated, most carry identical machine-precision-cap HR values, and the list is compositionally dominated by rRNA/snRNA/Y_RNA/SRP pseudogenes, olfactory receptor pseudogenes, and uncharacterized lncRNA loci. The biologically interpretable signal is confined to a small set of protein-coding candidates—**SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, and MIR182**—whose risk directions are individually consistent with plausible HCC aggressiveness mechanisms (amino-acid transport/metabolism, insulin/IGF signaling, developmental TF reactivation, oncomiR activity) but which do not form a single coherent program and lack independent-cohort validation. The most defensible next actions are, in order: (1) resolve the statistical artifact through penalized regression and low-expression filtering, (2) test the non-coding signature against tumor purity and cell composition, (3) validate SLC1A6 and IRS4 expression and function in independent HCC cohorts and cell models, and (4) treat every biological claim in this analysis as an exploratory hypothesis pending that validation, because external statistical validation was not performed and the raw effect sizes are not biologically interpretable.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=14, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
